SEC Form 4 · accession 0001127602-15-008869
LABCORP HOLDINGS INC. · LH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph L Herring
Officer — CEO of Covance Drug Division
Period of report
Feb 25, 2015
Accepted (ET)
Feb 27, 2015 · 6:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920148
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 25, 2015 | S | 30,718 | $121.5568 | D | 6,158 | D | |
| Common StockF3 | Feb 25, 2015 | S | 6,158 | $122.0279 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 17 shares that were excluded from the reporting person's Form 3 filed on February 25, 2015 due to a reporting software error.
- F2The price of $121.5568 per share represents a weighted average of sales prices ranging from $121.125 to $121.99 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- F3The price of $122.0279 per share represents a weighted average of sales prices ranging from $122.00 to $122.15 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.